Pharmaceutical Industry Reports Gastric and Esophageal Cancer Drugs Market | Page 2

REPORT DESCRIPTION
Gastric and Esophageal Cancer Drugs Market – Overview
Increasing number of cancer drugs in pipeline studies and rising involvement of key players for development of
cancer treatment are expected to propel gastric and esophageal cancer drugs market growth. For instance, in April
2016, Centre Hospitalier Universitaire de Besancon, initiated Phase 1 and Phase 2 clinical trial for Carboplatin to
determine the maximum tolerated dose (MTD) and recommended doses for phase II (RP2D) by considering the
treatment scheme of Dutch study for chemotherapy and radiotherapy. The study is conducted in elderly patients
with esophagus cancer. Carboplatin is an anticancer chemotherapy drug from alkylating agent category. The study
is estimated to complete by April 2024.
Moreover, in February 2017, Henan Cancer Hospital in collaboration with Jiangsu HengRui Medicine Co., Ltd.,
initiated Phase 2 exploratory clinical trial to evaluate the efficacy of Apatinib, treatment for advanced esophagus
cancer. Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor
receptor-2(VEGFR2).
However, high cost of therapy for the treatment of gastric and esophageal cancers is expected to restraint the
market growth. For instance, as per the report published in Healthday, in 2013, cancer patients paid US$ 207,000
a year for the treatment and medications while in 1995 the cost was US$ 54,100 a year.